ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Gemcitabine

Also written as “gemcitabine”, “gemcitabine hydrochloride” and “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”.

Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Biliary Tract Neoplasms, led by 30 companies.

Drug pageGemcitabine: every studyMany companies study it; this page follows only the 128 they lead. All 1,376 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 6, 2000128 company-led studies, 9 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only681 open or runningphase 3since Nov 6, 2000Nov 6, 2000May 2027phase 2 · NCT05999994
Hoffmann-La Roche181 open or runningphase 4since Mar 19, 2008Apr 17, 2007Mar 22, 2027phase 1 · NCT06624085
Pfizerits history only50 open or runningphase 3since Jan 21, 2000Jan 21, 2000none ahead
GlaxoSmithKlineits history only40 open or runningphase 2since May 23, 2003May 23, 2003none ahead
Amgenits history only30 open or runningphase 2since Jul 5, 2000Jul 5, 2000none ahead
Astellas Pharmaits history only20 open or runningphase 1since Apr 9, 2002Apr 9, 2002none ahead
NovoCureits history only20 open or runningphase 2since Oct 23, 2013Oct 23, 2013none ahead
Pierre Fabreits history only20 open or runningphase 2since Apr 16, 2012Apr 16, 2012none ahead
Sarah Cannon Research Instituteits history only20 open or runningphase 2since Apr 4, 2008Apr 4, 2008none ahead
Theriva Biologics SLits history only20 open or runningphase 1since Jan 21, 2014Jan 21, 2014none ahead

Also a collaborator on its studies: Ono Pharmaceutical, Baili-Bio (Chengdu) Pharmaceutical, AbbVie, Bristol-Myers Squibb, Criterium, AstraZeneca, PharmaBio Development, Johnson & Johnson, PPD DEVELOPMENT, LP, Merck, Sanofi and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Apr 17, 2007.

  1. Feb 9, 2010Phase 2 study in Non-Squamous Non-Small Cell Lung CancerNCT01077713 · 86 enrolled · Italy
  2. Aug 19, 2010Phase 2 study in Non-Squamous Non-Small Cell Lung CancerNCT01185847 · 90 enrolled · Belgium, France, Germany and more
  3. Sep 6, 2010Phase 2 study in Breast NeoplasmsNCT01201265 · 40 enrolled · India
  4. May 23, 2011Phase 1 study in Solid TumorNCT01359696 · 40 enrolled · United States, France
  5. Mar 23, 2012Phase 1 study in LymphomaNCT01564251 · 104 enrolled · United States, France
  6. Sep 11, 2012Phase 3 study in Ovarian NeoplasmsNCT01684878 · 208 enrolled · Austria, Belgium, Denmark and more
  7. Dec 5, 2013Phase 2 study in Urologic NeoplasmsNCT02006667 · 13 enrolled · Germany
  8. Sep 30, 2015Phase 2 study in Pancreatic NeoplasmsNCT02565641 · 63 enrolled · Korea, Republic of
  9. Jun 17, 2016Phase 3 study in Carcinoma, Transitional CellNCT02807636 · 1,213 enrolled · United States, Australia, Belgium and more
  10. Jun 9, 2017Phase 2 study in Pancreatic AdenocarcinomaNCT03193190 · 341 enrolled · United States, Germany, Japan and more
  11. Nov 7, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03337698 · 314 enrolled · United States, Australia, France and more
  12. Dec 22, 2017Phase 2 study in Uterine Cervical NeoplasmsNCT03386721 · 256 enrolled · United States, Belgium, France and more
  13. Mar 8, 2019Phase 2 study in Carcinoma, Transitional CellNCT03869190 · 272 enrolled · United States, France, Greece and more
  14. Oct 1, 2024Phase 1 study in LymphomaNCT06624085 · 50 enrolled · United States, Puerto Rico

Ahead

  1. Mar 22, 2027Primary completion: phase 1 study in LymphomaNCT06624085

TargetBeta

“Ribonucleoside-diphosphate reductase RR1 inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
HydroxyurearuleNorginephase 415

Studies

All 18 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06624085Lymphoma · United States, Puerto Rico1Active, not recruitingMar 22, 202750
NCT03869190Carcinoma, Transitional Cell · United States, France, Greece and more2TerminatedOct 8, 2025272
NCT03386721Uterine Cervical Neoplasms · United States, Belgium, France and more2TerminatedDec 30, 2021256
NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2TerminatedOct 14, 2025314
NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more2CompletedFeb 27, 2025341
NCT02807636Carcinoma, Transitional Cell · United States, Australia, Belgium and more3CompletedAug 31, 20221,213
NCT02565641Pancreatic Neoplasms · Korea, Republic of2CompletedSep 200663
NCT02006667Urologic Neoplasms · Germany2CompletedJan 201013
NCT01684878Ovarian Neoplasms · Austria, Belgium, Denmark and more3CompletedJan 30, 2015208
NCT01564251Lymphoma · United States, France1CompletedJan 11, 2018104
NCT01359696Solid Tumor · United States, France1CompletedMay 29, 201440
NCT01201265Breast Neoplasms · India2CompletedApr 201540
NCT01185847Non-Squamous Non-Small Cell Lung Cancer · Belgium, France, Germany and more2CompletedSep 201290
NCT01077713Non-Squamous Non-Small Cell Lung Cancer · Italy2CompletedJul 201486
NCT00846027Breast Neoplasms · Spain2CompletedDec 201190
NCT00701558Non-small Cell Lung Cancer Metastatic · Romania2CompletedOct 201020
NCT00642733Pancreatic Neoplasms · Mexico4TerminatedApr 20096
NCT00461708Pancreatic Neoplasms · Spain2CompletedNov 2010153

How it is read

Names in the registry

  • “Gemcitabine”, 113 entries
  • “gemcitabine”, 52 entries
  • “gemcitabine hydrochloride”, 17 entries
  • “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
  • “EndoTAG-1 and Gemcitabine”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.